App-Based Tracking Shows Cannabis May Temporarily Reduce Autism-Related Symptoms by 73% | Research

The takeaway

Self-identified autistic adults using a cannabis tracking app reported an average 73% reduction in symptom severity after use, with higher doses linked to greater reductions in repetitive behaviors and negative affect.

Autistic adults considering cannabis, clinicians treating autism, cannabis researchers

73% average reduction in self-reported symptom severity

What the researchers found

Among 111 self-identified autistic adults tracking cannabis use through the Strainprint app, symptom severity ratings dropped by an average of 73% from before to after cannabis use. More severe baseline symptoms were associated with greater reductions. Higher doses predicted greater improvements in repetitive behaviors, mental control, and negative affect.

Why it matters

Effective pharmacological treatments for core autism symptoms remain limited. This is one of the first studies to measure perceived acute effects of cannabis on autism-specific symptoms in adults, though the self-report design means the findings are preliminary.

The numbers in context

111 participants; average 73% reduction in symptom severity; dose remained stable over time (no escalation observed).

How the study worked

Retrospective analysis of anonymized archival data from the Strainprint app. 111 self-identified autistic adults tracked symptom changes before and after cannabis use across four domains: sensory sensitivity, repetitive behaviors, mental control, and negative affect.

What this study cannot tell us

Self-reported data from an app without a control group. Self-identified autism without clinical confirmation. No way to account for expectancy or placebo effects. The 73% improvement figure may reflect response bias, as users who find cannabis helpful are more likely to continue tracking.

How to read the evidence

Retrospective app-based self-report data without a control group or clinical diagnosis confirmation.

When this study was published

2025 publication

The bigger picture

Cannabis use is common in the autistic community, but research has lagged behind practice. While these self-reported improvements are striking, they reflect perceived acute effects rather than measured clinical outcomes, and placebo effects cannot be ruled out.

Questions still open

Would controlled clinical trials confirm these large self-reported symptom reductions?
Which specific cannabinoid profiles are most effective for different autism-related symptoms?

Common questions

Can cannabis help with autism symptoms?

In this study, self-identified autistic adults reported an average 73% reduction in symptom severity after cannabis use, including improvements in sensory sensitivity, repetitive behaviors, and negative affect. However, these are self-reported perceptions without a control group, so controlled trials are needed.

Did cannabis doses need to increase over time for autism symptoms?

No. Cannabis doses remained stable across time in this study, suggesting users did not develop tolerance requiring escalation for perceived symptom relief.

Read the original research

Acute effects of cannabis on core and co-occurring features associated with autism spectrum disorder in adults.

Scientific reports, 15(1), 39849

View on PubMed ↗Publisher’s paper ↗

Citation

Karhson, Debra S; LaFrance, Emily M; Cuttler, Carrie. (2025). Acute effects of cannabis on core and co-occurring features associated with autism spectrum disorder in adults.. Scientific reports, 15(1), 39849. https://doi.org/10.1038/s41598-025-23472-3